Tris DBA’s capacity to modulate autophagy and reduce mitochondrial ROS highlights the potential ability of targeting SIRT3 to reverse the metabolic dysregulation commonly observed in pancreatic cancer. Here, SIRT3 is linked to pancreatic neoplasm.